Roflumilast · Daliresp, Zoryve

What is Roflumilast?

Roflumilast is a phosphodiesterase 4 (PDE4) inhibitor that blocks breakdown of cyclic AMP, raising intracellular cyclic AMP levels. It is applied topically as a cream or foam and is studied in inflammatory skin conditions including hidradenitis suppurativa, vitiligo, seborrheic dermatitis, pruritus and atopic dermatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Daliresp, Zoryve, ARQ-151, B-9302-107

Drug type

Small molecule

Targets

phosphodiesterase 4 (PDE4)

Mechanism

Inhibitor of phosphodiesterase 4 (PDE4)

Pathways

cyclic AMP accumulation

Therapy area

Dermatology

Developer

Astrazeneca

In trials of

ARQT

FDA status

Approved as Daliresp, Zoryve (February 28, 2011), NDA022522 · FDA label

UNII

0P6C6ZOP5U

✅ FDA-approved uses

• Plaque Psoriasis (Zoryve)
• Atopic Dermatitis (Zoryve)
• COPD exacerbations in severe COPD associated with chronic bronchitis (Daliresp)

From the indications section of the FDA label (version of Jul 20, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic DermatitisHidradenitis SuppurativaITCHNon-segmental VitiligoAtopic Dermatitis (Eczema)Chronic Plaque PsoriasisPlaque PsoriasisPsoriasisSeborrheic Dermatitis

Sources

• FDA label (DailyMed)
• FDA label Zoryve (2026-07-20), indications
• FDA label Daliresp (2020-03-12), indications
• ClinicalTrials.gov NCT03392168
• ClinicalTrials.gov NCT03638258
• ClinicalTrials.gov NCT03764475
• ClinicalTrials.gov NCT04211363

Updated Oct 11, 2026.